Critical Advancements: Minimally Invasive Treatment for Severe COPD

Bronchoscopic lung volume reduction (BLVR) with endobronchial valves (EBV) is a guideline-based, FDA-approved standard of care treatment option for patients with severe emphysema. Over 25,000 patients have been treated globally with this minimally invasive therapy, clinically proven to improve lung function, exercise capacity, and quality of life.
The panel of pulmonologists will discuss the following:
· Urgency for new treatments for patients with severe COPD/emphysema
· Current treatment guidelines and optimizing patient care
· Clinical evidence and patient outcomes from BLVR with EBV
· Potential benefits and risks of BLVR with EBV
· Patient eligibility for BLVR with EBV treatment
· Next steps for patients—with or without BLVR with EBV treatment


All opinions expressed and information provided as part of this program are those of the presenters only. The content of this program has not been reviewed by CHEST and CHEST does not endorse or take any position regarding the contents, opinions or information associated with this program.

Copyright for this content is held by the American College of Chest Physicians. Permission to redistribute is required.